Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder

J Clin Psychiatry. 2018 Jan/Feb;79(1):17l11824. doi: 10.4088/JCP.17l11824.
No abstract available

Publication types

  • Controlled Clinical Trial
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Brain-Derived Neurotrophic Factor / blood
  • Brain-Derived Neurotrophic Factor / drug effects*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology
  • Excitatory Amino Acid Antagonists / therapeutic use
  • Humans
  • Infusions, Intravenous
  • Ketamine / pharmacology
  • Ketamine / therapeutic use
  • Middle Aged
  • Obsessive-Compulsive Disorder / blood
  • Obsessive-Compulsive Disorder / drug therapy*
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacology*
  • Oligopeptides / therapeutic use*
  • Young Adult

Substances

  • Brain-Derived Neurotrophic Factor
  • Excitatory Amino Acid Antagonists
  • Oligopeptides
  • Ketamine
  • GLYX-13 peptide